In case you missed it, @iamjohnoliver hosted an episode Sunday night on gender and racial bias in medicine. Here are a few of the studies on racial disparities he highlighted on the episode. 1/
@iamjohnoliver In a study of patients admitted to trauma centers in PA, authors found that patients admitted to hospitals with high concentrations of blacks had a 43% higher odds of death compared with patients admitted to hospitals treating low proportions of blacks. 2/ onlinelibrary.wiley.com/doi/full/10.11…
@iamjohnoliver In a well-cited 2016 paper, researchers found ~50% of medical students and residents surveyed reported at least one false belief about biological differences between blacks and whites (e.g. “black people’s skin is thicker than white people’s skin”). 3/ pnas.org/content/113/16…
@iamjohnoliver In this systematic review, the authors reviewed 20 years of data and found black vs. white disparities in “traumatic/surgical” and "non-traumatic/nonsurgical” pain management across all several settings; black patients were less likely to be treated. 4/
This was a study of >81,000 MCAT examinees (0.3% American Indian or Alaska Native, 21.3% Asian, 10.1% Black, 8.0% Hispanic, and 60.4% White) from 2015-2018.
I don’t know about y’all, but this was *the* hardest test I took. 😳
If y’all read *one* thing today, might I suggest this new article in @NEJM?
“The belief that Black people have denser bones, more muscle, or thicker skin led radiologists and technicians to use higher radiation exposure during x-ray procedures.”
In the latest issue of @JAMA_current, my mentor Michael Fine, Donna Washington and I were invited to discuss a new 📝 on disparities in SGLT2i and GLP1-RA use for diabetes and what it means for the field of #Pharmacoequity research.
2/ As has been discussed frequently over the last month with the insulin co-pay provisions in the #InflationReductionAct, >37 million people in the US have #diabetes.
Regrettably, underrepresented racial and ethnic groups folks have ⬆️ rates of diabetes.
3/ Even with the ⬆️ rates of diabetes, Black, Hispanic, and Asian patients in the US have been shown to have lower rates of #diabetes treatment, especially with the newer drugs available such as SGLT2i & GLP1-RAs.
In @JAMANetworkOpen, we found that VA patients with #AFib who experience homelessness had a 21% ⬇️ odds of receiving stroke-preventing anticoagulation (blood thinners).
Previously, if you looked up "homeless & atrial fibrillation" in PubMed, only 5 results came up.
This included a 2003 @JAMAInternalMed study that saw that Ohio Medicaid enrollees had ⬇️ use of warfarin if they had homelessness or inadequate housing.
As part of a special issue on 💊 costs & access, we wrote a broad review on “Pursuing #Pharmacoequity - Determinants, Drivers, and Pathways to Progress.
We talk social & health policy, research, patient & prescriber factors. 👇🏾👇🏾
2/ Understanding the multilevel determinants that influence equitable access to medications (and trying to do so in <5000 words (!) was the goal of our review.
With so many factors out there, we know we only began to scratch the surface.
Led by future Dr. @rohankhaz, we dive into the challenges & opportunities in ensuring that patients and communities most affected by the pandemic can get the care they need.
2/ At risk of redundancy, we previously discussed the challenges in achieving #Pharmacoequity, including in the pandemic, noting, “…For example, treatment of patients with #COVID19 has revealed substantial inequities in access to life-saving treatments.”
3/ That observation was supported by national CDC data from earlier this year, as well as a recent national analysis of Medicare enrollees that found that Black patients had a 23% ⬇️ odds of receiving monoclonal antibodies when diagnosed with #COVID19.